Phase 3 Long-Term Safety/Efficacy of SC Tanezumab in Hip/Knee OA
Chronic Pain · Osteoarthritis, Hip · Osteoarthritis, Knee
Enrolment: 3021 · Results not recorded
Biologic · Humanised monoclonal antibody that sequesters beta-nerve growth factor (target CHEMBL1649058); action type INHIBITOR, direct interaction true, disease efficacy true. ATC N02BG12. Not approved; ChEMBL max_phase 3.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Chronic Pain · Osteoarthritis, Hip · Osteoarthritis, Knee
Enrolment: 3021 · Results not recorded
Arthritis · Osteoarthritis · Osteoarthritis, Hip
Enrolment: 627 · Results not recorded
Bone Metastasis · Cancer Pain
Enrolment: 156 · Results not recorded
Osteoarthritis
Enrolment: 220 · Results not recorded
Low Back Pain
Enrolment: 849 · Results not recorded
Osteoarthritis, Knee · Osteoarthritis, Hip
Enrolment: 679 · Results not recorded
Cystitis, Interstitial
Enrolment: 205 · Results not recorded
Osteoarthritis, Knee
Enrolment: 83 · Results not recorded
Osteoarthritis · OA Knee Pain · Arthritis
Enrolment: 287 · Results not recorded
Osteoarthritis Pain · Chronic Low Back Pain · Pain Due to Interstitial Cystitis
Enrolment: 28 · Results not recorded
1 studies reported at therapy level; 3 evidence entries itemised.
Model: Medial meniscal tear (MMT) surgery of the knee, with additional delayed-treatment and mid-tibial amputation arms
Prophylactic tanezumab prevented the gait deficiency seen 3 to 7 days after MMT surgery and produced more severe cartilage damage, larger osteophytes, greater subchondral sclerosis and increased growth plate thickness in a time and dose related manner. Delaying treatment to 3 to 8 weeks after surge…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.
Extraction: mesh. Machine-extracted fields require source verification.
Extraction: mesh. Machine-extracted fields require source verification.